Eli Lilly finds impurity in compounded tirzepatide
Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.
BioNTech co-founders step down to launch new mRNA venture
UK health authorities join forces to champion foreign infectious disease trials
FDA approves GSK’s Wellcovorin for cerebral folate deficiency
Idorsia and Pharmalink sign agreement to distribute Quviviq
Building for decades: Dubai’s long game in life sciences
Analysis
View More
Themes
View MoreCinnaGen Enters EU Market with EMA Approval for Zandoriah®
CinnaGen today announced that the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Zandoriah® (teriparatide),…
More themes
Data Insights
View MoreCell & gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
Digital health and digital therapeutics (DTx) services and providers for the pharmaceutical industry
GlobalData Reports
View more
Digital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?